Literature DB >> 3665188

Normal natural killer cell activity in Hodgkin's disease patients in remission.

D Douer1, N Shaked, B Ramot.   

Abstract

Patients with untreated active Hodgkin's disease (HD) have a defect in cell-mediated immunity. After therapy many HD patients still have long lasting abnormalities in T cell number and function. We examined whether NK activity is also permanently impaired in HD patients in remission. The mean NK activity of peripheral blood lymphocytes from 42 patients who were disease-free for 6-150 months was not different from that of healthy controls. Augmentation of NK activity after treatment of the cells by interferon in vitro was equal for patients and controls. Normal NK activity in HD in remission was independent of disease stage, age, remission duration and mode of therapy. Measuring PHA-induced lymphocyte proliferation and NK activity simultaneously demonstrates that patients with impaired cell-mediated immunity do not have concomitant reduction of NK activity. We conclude that NK activity in HD in remission is independent of decreased T cell mediated immunity. In addition, NK is resistant to long term suppression by the chemotherapy and radiation protocols that are used in HD.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3665188      PMCID: PMC1542390     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  24 in total

1.  Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation.

Authors:  T Hercend; T Takvorian; A Nowill; R Tantravahi; P Moingeon; K C Anderson; C Murray; C Bohuon; A Ythier; J Ritz
Journal:  Blood       Date:  1986-03       Impact factor: 22.113

2.  Differences in the formation of normal T lymphocyte colonies by peripheral blood cells from patients with chronic lymphocytic leukemia and Hodgkin's disease.

Authors:  D Douer; L Sachs
Journal:  Clin Exp Immunol       Date:  1979-12       Impact factor: 4.330

3.  Effect of chemotherapeutic agents on natural cell-mediated cytotoxicity in mice.

Authors:  A Mantovani; W Luini; G Peri; A Vecchi; F Spreafico
Journal:  J Natl Cancer Inst       Date:  1978-11       Impact factor: 13.506

4.  Natural killer activity in spleens and lymph nodes from patients with Hodgkin's disease.

Authors:  L P Ruco; A Procopio; S Uccini; E Marcorelli; C D Baroni
Journal:  Cancer Res       Date:  1982-05       Impact factor: 12.701

5.  Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease.

Authors:  J Pedersen-Bjergaard; S O Larsen
Journal:  N Engl J Med       Date:  1982-10-14       Impact factor: 91.245

6.  Low natural in vivo resistance to syngeneic leukaemias in natural killer-deficient mice.

Authors:  K Kärre; G O Klein; R Kiessling; G Klein; J C Roder
Journal:  Nature       Date:  1980-04-17       Impact factor: 49.962

7.  Low natural killer cell activity in patients with malignant lymphoma.

Authors:  T Tursz; M C Dokhelar; M Lipinski; J L Amiel
Journal:  Cancer       Date:  1982-12-01       Impact factor: 6.860

8.  Human natural killer cells can inhibit clonogenic growth of fresh leukemic cells.

Authors:  M Beran; M Hansson; R Kiessling
Journal:  Blood       Date:  1983-03       Impact factor: 22.113

Review 9.  Natural killer cells: their roles in defenses against disease.

Authors:  R B Herberman; J R Ortaldo
Journal:  Science       Date:  1981-10-02       Impact factor: 47.728

10.  Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease.

Authors:  R I Fisher; V T DeVita; F Bostick; C Vanhaelen; D M Howser; S M Hubbard; R C Young
Journal:  Ann Intern Med       Date:  1980-05       Impact factor: 25.391

View more
  1 in total

Review 1.  Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma.

Authors:  Jodi Chiu; Daniel M Ernst; Armand Keating
Journal:  Front Immunol       Date:  2018-02-14       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.